Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06492837 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study With Mosunetuzumab and Zanubrutinib in R/R Follicular Lymphoma Patients

Study acronym: FIL_MOZART
StatusActive, Not Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Enrollment closed, study ongoing
    • Trial sites reduced: 24 → 20 locations
    v6
  2. Site details revised at 4 of 24 sitesv5
  3. Site details revised at 13 of 24 sitesv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 20 to 24
    • Start date changed from estimate of Sep 15, 2024 to Oct 23, 2024
    v3
  5. Study title shortened, about 2 wordsv2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is a Phase 2, multicenter study evaluating the efficacy and safety of mosunetuzumab + zanubrutinib (M+Z) used as salvage strategy in patients with R/R FL who have received at least one line of prior systemic therapy.
Trial Details
NCT Number NCT06492837
Lead Sponsor Fondazione Italiana Linfomi - ETS
Conditions
(from sponsor)		 Follicular Lymphoma
Related terms Lymphoma, Follicular
Enrollment 56 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov